Cargando…

STING agonist-boosted mRNA immunization via intelligent design of nanovaccines for enhancing cancer immunotherapy

Messenger RNA (mRNA) vaccine is revolutionizing the methodology of immunization in cancer. However, mRNA immunization is drastically limited by multistage biological barriers including poor lymphatic transport, rapid clearance, catalytic hydrolysis, insufficient cellular entry and endosome entrapmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Lei, Yi, Wenzhe, Zhang, Zehong, Shan, Xiaoting, Zhao, Zitong, Sun, Xiangshi, Wang, Jue, Wang, Hao, Jiang, Hualiang, Zheng, Mingyue, Wang, Dangge, Li, Yaping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484175/ https://www.ncbi.nlm.nih.gov/pubmed/37693123 http://dx.doi.org/10.1093/nsr/nwad214

Ejemplares similares

A STING-Activating Nanovaccine for Cancer Immunotherapy
por: Luo, Min, et al.
Publicado: (2017)

Light-controllable charge-reversal nanoparticles with polyinosinic-polycytidylic acid for enhancing immunotherapy of triple negative breast cancer
por: Fang, Lei, et al.
Publicado: (2022)

Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy
por: Su, Ting, et al.
Publicado: (2022)

Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
por: Jiang, Xiaoyi, et al.
Publicado: (2022)

Recent advances in developing active targeting and multi-functional drug delivery systems via bioorthogonal chemistry
por: Yi, Wenzhe, et al.
Publicado: (2022)

Correction: Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy
Publicado: (2022)

STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation
por: Zhang, Bo-Dou, et al.
Publicado: (2022)

Smart drug delivery systems to overcome drug resistance in cancer immunotherapy
por: Yi, Wenzhe, et al.
Publicado: (2023)

Effects of Combinatorial Ubiquitinated Protein-Based Nanovaccine and STING Agonist in Mice With Drug-Resistant and Metastatic Breast Cancer
por: Huang, Fang, et al.
Publicado: (2021)

Acid-switchable nanoparticles induce self-adaptive aggregation for enhancing antitumor immunity of natural killer cells
por: Sun, Xiangshi, et al.
Publicado: (2023)

Dual-responsive nanovaccine for cytosolic delivery of antigens to boost cellular immune responses and cancer immunotherapy
por: Sui, Yang, et al.
Publicado: (2022)

In Situ Cocktail Nanovaccine for Cancer Immunotherapy
por: Liu, Mohan, et al.
Publicado: (2023)

Nanovaccines: Merits, and diverse roles in boosting antitumor immune responses
por: Yin, Qiliang, et al.
Publicado: (2022)

Engineering autologous tumor cell vaccine to locally mobilize antitumor immunity in tumor surgical bed
por: Fang, Lei, et al.
Publicado: (2020)

Anti-triple-negative breast cancer metastasis efficacy and molecular mechanism of the STING agonist for innate immune pathway
por: Lu, Xing, et al.
Publicado: (2023)

A Magnetic Nanovaccine Enhances Cancer Immunotherapy
por: Guo, Yugang, et al.
Publicado: (2019)

Artificially cloaked viral nanovaccine for cancer immunotherapy
por: Fusciello, Manlio, et al.
Publicado: (2019)

CpG-Based Nanovaccines for Cancer Immunotherapy
por: Chen, Wenqiang, et al.
Publicado: (2021)

Nanovaccines for Cancer Prevention and Immunotherapy: An Update Review
por: Fang, Xingliang, et al.
Publicado: (2022)

Research progress of nanovaccine in anti-tumor immunotherapy
por: Yao, Min, et al.
Publicado: (2023)

Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy
por: Chen, Jie, et al.
Publicado: (2021)

Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy
por: Dong, Ying, et al.
Publicado: (2020)

Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
por: Motedayen Aval, Leila, et al.
Publicado: (2020)

Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy
por: Go, Eun-Jin, et al.
Publicado: (2020)

Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy
por: Shi, Chen, et al.
Publicado: (2023)

Tumor-targeted delivery of a STING agonist improves cancer immunotherapy
por: Wu, You-tong, et al.
Publicado: (2022)

Correction: Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy
por: Shi, Chen, et al.
Publicado: (2023)

Combination of STING and TLR 7/8 Agonists as Vaccine Adjuvants for Cancer Immunotherapy
por: Bhatnagar, Shubhmita, et al.
Publicado: (2022)

Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy
por: Zhu, Guizhi, et al.
Publicado: (2017)

Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response
por: Zhang, Lele, et al.
Publicado: (2021)

Co-delivery of phagocytosis checkpoint and STING agonist by a Trojan horse nanocapsule for orthotopic glioma immunotherapy
por: Zhou, Ying, et al.
Publicado: (2022)

Immunosuppression Reversal Nanovaccines Substituting Dendritic Cells for Personalized Cancer Immunotherapy
por: Chen, Hu, et al.
Publicado: (2022)

STING activation in cancer immunotherapy
por: Su, Ting, et al.
Publicado: (2019)

Probiotics formulation and cancer nanovaccines show synergistic effect in immunotherapy and prevention of colon cancer
por: Xu, Xiangxiang, et al.
Publicado: (2023)

STING Agonists as Cancer Therapeutics
por: Amouzegar, Afsaneh, et al.
Publicado: (2021)

A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer
por: Ni, Qianqian, et al.
Publicado: (2020)

Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy
por: Shae, Daniel, et al.
Publicado: (2019)

Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy
por: Zheng, Huan, et al.
Publicado: (2022)

Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives
por: Huang, Cuiqing, et al.
Publicado: (2023)

Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapy
por: Wang, Bin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lgf2fkedhi1l0ohp3fs5ltimi1